Power-speed-endurance Profile (Cycling/Rowing) : Optimize Performance of the French Athletes at the Paris Olympics 2024

Healthy Volunteers Clinical Trial

— THPCA2024  

Official title:

Description and Determinants of the Power-speed-endurance Profile (PVE) in Cycling and Rowing to Optimize the Performance of the French Athletes at the Paris Olympics 2024

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05314543
• Other study ID #: 21CH145
• Secondary ID: 2021-A02341-40
• Status: Recruiting
• Phase: N/A
• Start date: November 29, 2021
• Est. completion date: August 2024

Study information

• Verified date: April 2024
• Source: Centre Hospitalier Universitaire de Saint Etienne
• Contact: Léonard FEASSON, PhD
• Phone: (0)477120383
• Email: leonard.feasson[@]chu-st-etienne.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

As part of the preparation at the Paris 2024 Olympic Games, the French rowing and cycling federations and a consortium of researchers met to reach an ultimate goal: to increase the number of medals in these two disciplines for Paris 2024 Olympics.

Description:

The objective of this study is to evaluate the maximum capacity of power production of athletes by describing their power-endurance profile and the physiological factors underlying this maximum power generation capacity. These assessments will guide coaches and athletes for: 1. the best use of athletes' physical abilities (for race strategy, cycling gear ratio or rowing levers) 2. adaptation of training program to improve the maximum capacity of power production of the athletes, in order to increase the number of medals at the Paris Olympics 2024.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: August 2024
• Est. primary completion date: August 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• experienced, well-trained (national to international level) rowers and cyclists
• written consent

Exclusion Criteria:

• taking medications interfering with measured parameters
• contraindication to competitive sport practice
• currently participating in an other structured exercise program
• muscular, bone or joint injuries
• neurologic disease
• pregnant

Related Conditions & MeSH terms

• Healthy Volunteers
• Performance

Intervention

Other:
• Hypoxia
Subjects will be subjected to mild hypoxia simulating an altitude of 1750 m (normobaric hypoxia). Hypoxia decreases oxygen supply to tissue and limit exercise capacity. For this, the subjects will inhale a gas mixture depleted in oxygen (enriched in nitrogen). The barometric pressure at 1500 m being 621 mmHg, PIO2 at this altitude (PIO2 = (621 - 47) x 21%) is 120.5 mmHg. For sea level altitude where the barometric pressure is 760 mmHg, the hypoxic gas mixture should contain (x = 120.5 / (760 - 47)) 16.8% O2. Thus, by inhaling a gas mixture that is oxygen-depleted from 21 to 16.8%, subjects (will simulate the altitude of 1750 and) will experience the equivalent of a 20% reduction in oxygen supply.

Locations

Country	Name	City	State
France	CEPART	Le Bourget-du-Lac
France	Chu Nantes	Nantes
France	Chu Saint-Etienne	Saint-Étienne

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Saint Etienne

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum force produced at zero speed in a fatigue-free condition	F0i measurement	Month : 3
Primary	Speed in a fatigue-free condition	V0i measurement	Month : 3
Primary	Maximum force produced at zero speed at the end of the 3 min.	F0e measurement	Month : 3
Primary	Speed up produced at the end of the 3 min.	V0e measurement	Month : 3
Secondary	Maximal oxygen uptake (VO2max)	Cardiac stress test	At inclusion
Secondary	Maximal Ventilation (VEmax)	Cardiac stress test	At inclusion
Secondary	Cardiac output (QCmax)	Cardiac stress test	At inclusion
Secondary	Maximal cardiac frequency (fcmax)	Cardiac stress test	At inclusion
Secondary	Fibre type determination	Muscle biopsy of the vastus lateralis	Month : 2
Secondary	Microvasculature analysis	Muscle biopsy of the vastus lateralis	Month : 2
Secondary	Muscle enzyme activity (Phosphofructokinase (PFK), lactate dehydrogenase (LDH), citrate synthase (CS) et cyclo-oxygenase (COx))	Muscle biopsy of the vastus lateralis	Month : 2
Secondary	Maximal voluntary force (N)	Comparison before and after exercise	Month : 9
Secondary	Rate of force development	Comparison of force development	Month : 9
Secondary	Evoked forces (N)	Ratio of evoked force at low and high frequencies	Month : 9